메뉴 건너뛰기




Volumn 6, Issue 6, 2011, Pages 657-667

Ocular drug delivery for bioactive proteins

Author keywords

Antibody; Bioactive proteins; Controlled release; Cytokine; Drug targeting; Intraocular drug delivery systems

Indexed keywords

AFLIBERCEPT; AGENTS ACTING ON THE EYE; BETA INTERFERON; BEVACIZUMAB; DEXTRAN; FIBROBLAST GROWTH FACTOR; GELATIN; GELLING AGENT; MICROSPHERE; MITOMYCIN C; PENTETIC ACID; POT 4; RANIBIZUMAB; UNCLASSIFIED DRUG;

EID: 82455192444     PISSN: 17469899     EISSN: 17469902     Source Type: Journal    
DOI: 10.1586/eop.11.66     Document Type: Review
Times cited : (8)

References (41)
  • 1
    • 0026681119 scopus 로고
    • Prevalence of age-related maculopathy: The beaver dam eye study
    • Klein R, Klein BEK, Linton KLP. Prevalence of age-related maculopathy: the Beaver Dam Eye study. Ophthalmology 99, 933-943 (1992).
    • (1992) Ophthalmology , vol.99 , pp. 933-943
    • Klein, R.1    Klein, B.E.K.2    Linton, K.L.P.3
  • 2
    • 0000180036 scopus 로고
    • Subretinal neovascularization
    • Ryan SJ Ed. St. Louis MO USA
    • Ryan SJ, Stout JT, Dugel PU. Subretinal neovascularization. In:Retina . Ryan SJ (Ed.). St. Louis, MO, USA, 1027-1047 (1994).
    • (1994) Retina , pp. 1027-1047
    • Ryan, S.J.1    Stout, J.T.2    Dugel, P.U.3
  • 3
    • 33749445317 scopus 로고    scopus 로고
    • Marina study group: Ranibizumab for neovascular age-related macular degeneration
    • Rosenfeld PJ, Brown DM, Heier JS et al. MARINA Study Group: ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1419-1431 (2006).
    • (2006) N. Engl. J. Med. , vol.355 , pp. 1419-1431
    • Rosenfeld, P.J.1    Brown, D.M.2    Heier, J.S.3
  • 4
    • 33749451356 scopus 로고    scopus 로고
    • Anchor study group: Ranibizumab versus verteporfin for neovascular age-related macular degeneration
    • Brown DM, Kaiser PK, Michels M et al. ANCHOR Study Group: ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med. 355, 1432-1444 (2006).
    • (2006) N. Engl. J. Med. , vol.355 , pp. 1432-1444
    • Brown, D.M.1    Kaiser, P.K.2    Michels, M.3
  • 5
    • 77953248909 scopus 로고    scopus 로고
    • Medical devices for the treatment of eye diseases
    • Yasukawa T, Ogura Y. Medical devices for the treatment of eye diseases. Handb. Exp. Pharmacol. 197, 469-489 (2010).
    • (2010) Handb. Exp. Pharmacol. , vol.197 , pp. 469-489
    • Yasukawa, T.1    Ogura, Y.2
  • 7
    • 0002611505 scopus 로고
    • Ocular pharmacokinetics
    • Sears ML Ed. Springer NY USA
    • Maurice DM, Mishima S. Ocular pharmacokinetics. In:Pharmacology of the Eye . Sears ML (Ed.). Springer, NY, USA, 19-116 (1984).
    • (1984) Pharmacology of the Eye , pp. 19-116
    • Maurice, D.M.1    Mishima, S.2
  • 9
    • 0029347541 scopus 로고
    • Ocular drug delivery: Conventional ocular formulations
    • Lang LC. Ocular drug delivery: conventional ocular formulations. Adv. Drug Deliv. Rev. 16, 39-43 (1995).
    • (1995) Adv. Drug Deliv. Rev. , vol.16 , pp. 39-43
    • Lang, L.C.1
  • 10
    • 47249126766 scopus 로고    scopus 로고
    • When nanotechnology meets the ocular surface
    • Bucolo C, Maltese, A, Drago F. When nanotechnology meets the ocular surface. Expert Rev. Ophthalmol. 3(3), 325-332 (2008).
    • (2008) Expert Rev. Ophthalmol. , vol.3 , Issue.3 , pp. 325-332
    • Bucolo, C.1    Maltese, A.2    Drago, F.3
  • 11
    • 79956218863 scopus 로고    scopus 로고
    • Ranibizumab and bevacizumab for neovascular age-related macular degeneration
    • CATT Research Group:
    • CATT Research Group: Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GL. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N. Engl. J. Med. 364, 1897-1908 (2011).
    • (2011) N. Engl. J. Med. , vol.364 , pp. 1897-1908
    • Martin, D.F.1    Maguire, M.G.2    Ying, G.S.3    Grunwald, J.E.4    Fine, S.L.5    Jaffe, G.L.6
  • 12
    • 0037143764 scopus 로고    scopus 로고
    • VEGF-Trap: A VEGF blocker with potent antitumor effects
    • USA
    • Holash J, Davis S, Papadopoulos N et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc. Natl Acad. Sci. USA 99, 11393-11398 (2002).
    • (2002) Proc. Natl Acad. Sci. , vol.99 , pp. 11393-11398
    • Holash, J.1    Davis, S.2    Papadopoulos, N.3
  • 15
    • 0033951011 scopus 로고    scopus 로고
    • Experimental corneal neovascularization by basic fibroblast growth factor impregnated in gelatin hydrogel
    • Yang CF, Yasukawa T, Kimura H et al. Experimental corneal neovascularization by basic fibroblast growth factor impregnated in gelatin hydrogel. Ophthalmic Res. 32, 19-24 (2000).
    • (2000) Ophthalmic Res. , vol.32 , pp. 19-24
    • Yang, C.F.1    Yasukawa, T.2    Kimura, H.3
  • 16
    • 61549121751 scopus 로고    scopus 로고
    • Initial bone regeneration around fenestrated implants in Beagle dogs using basis fibroblast growth factor-gelatin hydrogel complex with varying biodegradation rates
    • Akagawa Y, Kubo T, Koretake K et al. Initial bone regeneration around fenestrated implants in Beagle dogs using basis fibroblast growth factor-gelatin hydrogel complex with varying biodegradation rates. J. Prosthodont. Res. 53, 41-47 (2009).
    • (2009) J. Prosthodont. Res. , vol.53 , pp. 41-47
    • Akagawa, Y.1    Kubo, T.2    Koretake, K.3
  • 17
  • 18
    • 33744801076 scopus 로고    scopus 로고
    • Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomized eye
    • Kosobucki BR, Freeman WR, Cheng L. Photographic estimation of the duration of high dose intravitreal triamcinolone in the vitrectomized eye. Br. J. Ophthalmol. 90, 705-708 (2006).
    • (2006) Br. J. Ophthalmol. , vol.90 , pp. 705-708
    • Kosobucki, B.R.1    Freeman, W.R.2    Cheng, L.3
  • 19
    • 85028109108 scopus 로고    scopus 로고
    • Sustained release of a monoclonal antibody from electrochemically prepared porous silica for the treatment of age related macular degeneration
    • E-Abstract 3488
    • Andrew JS, Anglin EJ, Cunin F et al. Sustained release of a monoclonal antibody from electrochemically prepared porous silica for the treatment of age related macular degeneration. Invest. Ophthalmol. Vis. Sci. 50 (2009) (E-Abstract 3488).
    • (2009) Invest. Ophthalmol. Vis. Sci. , vol.50
    • Andrew, J.S.1    Anglin, E.J.2    Cunin, F.3
  • 20
    • 82455180476 scopus 로고    scopus 로고
    • Resorbable sustained intra-ocular release system for monoclonal antibodies and other large molecules
    • E-Abstract 5333
    • Hampton SM, Voigt A, Reiff A. Resorbable sustained intra-ocular release system for monoclonal antibodies and other large molecules. Invest. Ophthalmol. Vis. Sci. 51, (2010) (E-Abstract 5333).
    • (2010) Invest. Ophthalmol. Vis. Sci. , vol.51
    • Hampton, S.M.1    Voigt, A.2    Reiff, A.3
  • 21
    • 26844530250 scopus 로고    scopus 로고
    • Stimulation of neurite outgrowth by neurotrophins delivered from degradable hydrogels
    • Burdick JA, Ward M, Liang E, Young MJ, Langer R. Stimulation of neurite outgrowth by neurotrophins delivered from degradable hydrogels. Biomaterials 27, 452-459 (2006).
    • (2006) Biomaterials , vol.27 , pp. 452-459
    • Burdick, J.A.1    Ward, M.2    Liang, E.3    Young, M.J.4    Langer, R.5
  • 22
    • 69249222639 scopus 로고    scopus 로고
    • New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis
    • Lajavardi L, Camelo S, Agnely F et al. New formulation of vasoactive intestinal peptide using liposomes in hyaluronic acid gel for uveitis. J. Control Release 139, 22-30 (2009).
    • (2009) J. Control Release , vol.139 , pp. 22-30
    • Lajavardi, L.1    Camelo, S.2    Agnely, F.3
  • 23
    • 79952118241 scopus 로고    scopus 로고
    • Suppression of drusen formation by compstatin a peptide inhibitor of complement C3 activation on cynomolgus monkey with early-onset macular degeneration
    • Chi ZL, Yoshida T, Lambris JD, Iwata T. Suppression of drusen formation by compstatin, a peptide inhibitor of complement C3 activation, on cynomolgus monkey with early-onset macular degeneration. Adv. Exp. Med. Biol. 703, 127-135 (2010).
    • (2010) Adv. Exp. Med. Biol. , vol.703 , pp. 127-135
    • Chi, Z.L.1    Yoshida, T.2    Lambris, J.D.3    Iwata, T.4
  • 24
    • 8544270082 scopus 로고    scopus 로고
    • Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration results of a prospective randomized placebo-controlled clinical trial
    • Pharmacological Therapy for Macular Degeneration Study Group
    • Pharmacological Therapy for Macular Degeneration Study Group. Interferon alfa-2a is ineffective for patients with choroidal neovascularization secondary to age-related macular degeneration. Results of a prospective randomized placebo-controlled clinical trial. Arch. Ophthalmol. 115, 865-872 (1997).
    • (1997) Arch. Ophthalmol. , vol.115 , pp. 865-872
  • 25
    • 0036750664 scopus 로고    scopus 로고
    • Pegylated interferons for the treatment of chronic hepatitis C infection
    • Luxon BA, Grace M, Brassard D, Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection. Clin. Ther. 24, 1363-1383 (2002).
    • (2002) Clin. Ther. , vol.24 , pp. 1363-1383
    • Luxon, B.A.1    Grace, M.2    Brassard, D.3    Bordens, R.4
  • 26
    • 0022858683 scopus 로고
    • A new concept for macromolecular therapeutics in cancer chemotherapy: Mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs
    • Matsumura Y, Maeda H. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res. 46, 6387-6392 (1986).
    • (1986) Cancer Res. , vol.46 , pp. 6387-6392
    • Matsumura, Y.1    Maeda, H.2
  • 27
    • 0036184270 scopus 로고    scopus 로고
    • Targeting of interferon to choroidal neovascularization by use of dextran and metal coordination
    • Yasukawa T, Kimura H, Tabata Y et al. Targeting of interferon to choroidal neovascularization by use of dextran and metal coordination. Invest. Ophthalmol. Vis. Sci. 43, 842-848 (2002).
    • (2002) Invest. Ophthalmol. Vis. Sci. , vol.43 , pp. 842-848
    • Yasukawa, T.1    Kimura, H.2    Tabata, Y.3
  • 28
    • 2342586114 scopus 로고    scopus 로고
    • Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470
    • Satchi-Fainaro R, Puder M, Davies JW et al. Targeting angiogenesis with a conjugate of HPMA copolymer and TNP-470. Nat. Med. 10, 255-261 (2004).
    • (2004) Nat. Med. , vol.10 , pp. 255-261
    • Satchi-Fainaro, R.1    Puder, M.2    Davies, J.W.3
  • 29
    • 0034442273 scopus 로고    scopus 로고
    • Active drug targeting with immunoconjugates to choroidal neovascularization
    • Yasukawa T, Kumura H, Tabata Y et al. Active drug targeting with immunoconjugates to choroidal neovascularization. Curr. Eye Res. 21, 952-961 (2000).
    • (2000) Curr. Eye Res. , vol.21 , pp. 952-961
    • Yasukawa, T.1    Kumura, H.2    Tabata, Y.3
  • 31
    • 0029843947 scopus 로고    scopus 로고
    • Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases
    • USA
    • Friedlander M, Theesfeld CL, Sugita M et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl Acad. Sci. USA 93, 9764-9769 (1996).
    • (1996) Proc. Natl Acad. Sci. , vol.93 , pp. 9764-9769
    • Friedlander, M.1    Theesfeld, C.L.2    Sugita, M.3
  • 32
    • 0032961301 scopus 로고    scopus 로고
    • Expression of vascular endothelial growth factor and its receptor KDR/flk-1 mRNA in experimental choroidal neovascularization
    • Wada M, Ogata N, Otsuji T, Uyama M. Expression of vascular endothelial growth factor and its receptor (KDR/flk-1) mRNA in experimental choroidal neovascularization. Curr. Eye. Res. 18, 203-213 (1999).
    • (1999) Curr. Eye. Res. , vol.18 , pp. 203-213
    • Wada, M.1    Ogata, N.2    Otsuji, T.3    Uyama, M.4
  • 33
    • 0038147049 scopus 로고    scopus 로고
    • Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization
    • Sakurai E, Taguchi H, Anand A et al. Targeted disruption of the CD18 or ICAM-1 gene inhibits choroidal neovascularization. Invest. Ophthalmol. Vis. Sci. 44, 2743-2749 (2003).
    • (2003) Invest. Ophthalmol. Vis. Sci. , vol.44 , pp. 2743-2749
    • Sakurai, E.1    Taguchi, H.2    Anand, A.3
  • 34
    • 0031657921 scopus 로고    scopus 로고
    • Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularization in the rat
    • Shen WY, Yu MJ, Barry CJ, Constable IJ, Rakoczy PE. Expression of cell adhesion molecules and vascular endothelial growth factor in experimental choroidal neovascularization in the rat. Br. J. Ophthalmol. 82, 1063-1071 (1998).
    • (1998) Br. J. Ophthalmol. , vol.82 , pp. 1063-1071
    • Shen, W.Y.1    Yu, M.J.2    Barry, C.J.3    Constable, I.J.4    Rakoczy, P.E.5
  • 35
    • 67650457597 scopus 로고    scopus 로고
    • CCR3 is a target for age-related macular degeneration diagnosis and therapy
    • Takeda A, Baffi JZ, Kleinman ME et al. CCR3 is a target for age-related macular degeneration diagnosis and therapy. Nature 460, 225-230 (2009).
    • (2009) Nature , vol.460 , pp. 225-230
    • Takeda, A.1    Baffi, J.Z.2    Kleinman, M.E.3
  • 36
    • 82455221503 scopus 로고    scopus 로고
    • Sustained intraocular delivery of a receptor antibody using an encapsulated cell technology implant
    • E-Abstract 5317
    • Kauper K, Stabila P, Elliot S et al. Sustained intraocular delivery of a receptor antibody using an encapsulated cell technology implant. Invest. Ophthalmol. Vis. Sci. 51 (2010) (E-Abstract 5317).
    • (2010) Invest. Ophthalmol. Vis. Sci. , vol.51
    • Kauper, K.1    Stabila, P.2    Elliot, S.3
  • 37
    • 79955128744 scopus 로고    scopus 로고
    • Nuclear targeted delivery of macromolecules to retina and cornea
    • Binder C, Read SP, Cashman SM, Kumar-Singh R. Nuclear targeted delivery of macromolecules to retina and cornea. J. Gene Med. 13, 158-170 (2011).
    • (2011) J. Gene Med. , vol.13 , pp. 158-170
    • Binder, C.1    Read, S.P.2    Cashman, S.M.3    Kumar-Singh, R.4
  • 38
    • 77957194820 scopus 로고    scopus 로고
    • Non-viral siRNA delivery into the mouse retina in vivo
    • Turchinovich A, Zoidl G, Dermietzel R. Non-viral siRNA delivery into the mouse retina in vivo. BMC Ophthalmol. 10, 25 (2010).
    • (2010) BMC Ophthalmol. , vol.10 , pp. 25
    • Turchinovich, A.1    Zoidl, G.2    Dermietzel, R.3
  • 39
    • 75749121523 scopus 로고    scopus 로고
    • Suppression of ICAM-1 in retinal and choroidal endothelial cells by plasmid small-interfering RNAs in vivo
    • Hirano Y, Sakurai E, Matsubara A, Ogura Y. Suppression of ICAM-1 in retinal and choroidal endothelial cells by plasmid small-interfering RNAs in vivo. Invest. Ophthalmol. Vis. Sci. 51, 508-515 (2010).
    • (2010) Invest. Ophthalmol. Vis. Sci. , vol.51 , pp. 508-515
    • Hirano, Y.1    Sakurai, E.2    Matsubara, A.3    Ogura, Y.4
  • 40
    • 77949423366 scopus 로고    scopus 로고
    • Inhibitory efficacy of hypoxia-inducible factor 1alpha short hairpin RNA plasmid DNA-loaded poly d l-lactide-co-glycolide nanoparticles on choroidal neovascularization in a laser-induced rat model
    • Zhang C, Wang YS, Wu H et al. Inhibitory efficacy of hypoxia-inducible factor 1alpha short hairpin RNA plasmid DNA-loaded poly (d, l-lactide-co- glycolide) nanoparticles on choroidal neovascularization in a laser-induced rat model. Gene Ther. 17, 338-351 (2010).
    • (2010) Gene Ther. , vol.17 , pp. 338-351
    • Zhang, C.1    Wang, Y.S.2    Wu, H.3
  • 41
    • 11144232135 scopus 로고    scopus 로고
    • Sustained secretion of ciliary neurotrophic factor to the vitreous using the encapsulated cell therapy-based NT-501 intraocular device
    • Thanos CG, Bell WJ, O'Rourke P et al. Sustained secretion of ciliary neurotrophic factor to the vitreous, using the encapsulated cell therapy-based NT-501 intraocular device. Tissue Eng. 10, 1617-1622 (2004).
    • (2004) Tissue Eng. , vol.10 , pp. 1617-1622
    • Thanos, C.G.1    Bell, W.J.2    O'Rourke, P.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.